WHO ICTRP trial
A multicenter phase 2 study of nivolumab combined with ipilimumab in patients…
EUCTR2016-003946-99-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2016-003946-99-ES |
|---|---|
| Public title | A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood |
| Scientific title | A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood |
| Primary sponsor | Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI) |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Spain |
| Conditions | Pediatric solid tumors presenting in adulthood MedDRA version: 19.1 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Opdivo Product Name: Nivolumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Nivolumab CAS Number: EU/1/15/1014 Current Sponsor code: BMS-936558 Other descriptive name: NIVOLUMAB Concentration… |
| Registration date | Mar 31, 2017 |
| Target size | 98 |
| Secondary IDs | GETHI021 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: